Burgess Still Wants to Limit FDA LDT Oversight
This article was originally published in The Gray Sheet
Executive Summary
Despite failing to move on a bill to restrict FDA oversight of lab developed tests (LDT) or reintroducing the bill in recent sessions, Rep. Michael Burgess, R-Texas, says he still supports the idea and is still working on trying to limit the agency's authority.